Directory of registries

Registry of patients with essential thrombocythaemia or thrombocythaemia associated with another myeloproliferative disorder who have been treated with anagrelide (Thromboreductin®).

start of the project: September 2011

end of the project: March 2019

Thromboreductin is a multicentre, prospective, non-interventional post-authorisation safety study. The project was initiated at the Institute of Biostatistics and Analyses of the Masaryk University (IBA MU) and has continued at the Institute of Biostatistics and Analyses Ltd (IBA Ltd), a university company.

Thromboreductin® has been registered in the Czech Republic for the treatment of essential thrombocythaemia (ET), which is classified as a rare disease due to its incidence rate.

Development and maintenance of a database of ET patients treated with Thromboreductin®, including a subsequent analysis of its safety profile and the verification of drug effectiveness in routine clinical practice, were prerequisites for this medicinal product to be registered by the State Institute for Drug Control (SUKL).

Primary objective of the project:

  • assessment of safety profile of anagrelide (Thromboreductin®)

Secondary objectives of the project:

  • assessment of effectiveness of anagrelide (Thromboreductin®) in routine clinical practice,
  • collection of basic epidemiological data on the monitored population of patients.

Other important information:

  • Expert guarantor: Prof. Miroslav Penka, MD, PhD
  • Funding: AOP Orphan Pharmaceuticals, AG